ABSTRACT
Chagas disease
CHAGAS DISEASE
The authors declare a conflict of interest. J.A. acted as a consultant to Bayer for the design, conduct and review of the CHICO and CHICO SECURE studies. U.G. is an employee of Bayer AG (Berlin, Germany). E.H. is an employee of Bayer US LLC (Whippany, New Jersey, USA). G.M. received personal fees from Bayer during the conduct of the study. O.D. is an employee of Bayer Healthcare Co., Ltd. (Shanghai, China). V.S., T.R., and J.J.P.R. have no conflicts of interest to disclose.Nifurtimox is recommended for the treatment of Chagas disease; however, long-term follow-up data are scarce. This prolonged follow-up phase of the prospective, historically controlled, CHICO clinical trial evaluated seronegative conversion in pediatric patients aged <18 years with Chagas disease who were followed for 4 years after nifurtimox treatment. Patients were randomly assigned 2:1 to nifurtimox 60-day or 30-day regimens comprising 10 to 20 mg/kg/day for patients aged <12 years and body weight <40 kg, and 8 to 10 mg/kg/day for those aged ≥12 years and body weight ≥40 kg. Anti-